Back to top

oncology-screening: Archive

Shaun Pruitt

Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank

Adding to the unusually strong performance of the Russell 2000 this year, these top performers may certainly serve as stocks to add to your watchlist

BETRNegative Net Change COGTPositive Net Change CELCPositive Net Change RGCNegative Net Change OPENNegative Net Change IWMNegative Net Change

Urmimala Biswas

Tempus AI: Revenue Mix and 2026 Growth Outlook Explained

Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.

EXASPositive Net Change GHPositive Net Change TEMNegative Net Change

Bryan Hayes

Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026

Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.

LLYPositive Net Change

Zacks Equity Research

COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know

Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.

ADMANegative Net Change EDITNegative Net Change COGTPositive Net Change ARQTNegative Net Change

Zacks Equity Research

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

MRKPositive Net Change GILDNegative Net Change ADMANegative Net Change ARQTNegative Net Change